Skip to Content

T21 (Risedronate Sodium Delayed-Release 35 mg)

Pill with imprint T21 is White, Elliptical / Oval and has been identified as Risedronate Sodium Delayed-Release 35 mg. It is supplied by Teva Pharmaceuticals USA Inc.

Risedronate is used in the treatment of prevention of osteoporosis; osteoporosis; paget's disease and belongs to the drug class bisphosphonates. Risk cannot be ruled out during pregnancy. Risedronate 35 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for T21

Risedronate sodium delayed-release 35 mg T21
Risedronate sodium delayed-release 35 mg T21
Risedronate sodium delayed-release 35 mg T21

Risedronate Sodium Delayed-Release

Imprint:
T21
Strength:
35 mg
Color:
White
Shape:
Elliptical / Oval
Availability:
Prescription only
Drug Class:
Bisphosphonates
Pregnancy Category:
C - Risk cannot be ruled out
CSA Schedule:
Not a controlled drug
Labeler / Supplier:
Teva Pharmaceuticals USA Inc
National Drug Code (NDC):
00093-5509

Get help with Imprint Code FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide